Nanoparticle-stabilized nanocapsules and methods of preparation and use for nucleic acid delivery
The invention provides nanoparticle-stabilized nanocapsules, and methods of their preparation and use in delivery of therapeutics, such as nucleic acids. Various embodiments disclosed relate to a nanoparticle-stabilized nanocapsule. Various embodiments disclosed relate to nanoparticle-stabilized nanocapsules for nucleic acid delivery into cells. Various embodiments provide methods of using the nanocapsule for in vivo delivery of the nucleic acid materials.
1. A nanoparticle-stabilized nanocapsule, consisting of:
a nanodroplet comprising an amphiphilic fluid, wherein the amphiphilic fluid is a compound having the structure of (C 5 -C 50 )hydrocarbyl-COOH, wherein the (C 5 -C 50 )hydrocarbyl is substituted or unsubstituted;
a plurality of nanoparticles deposed on a surface of the nanodroplet, each nanoparticle consisting of
a quantum dot comprising one or more of gold, iron oxide, cobalt ferrite, and silica, and
a ligand consisting of a (C 0 -C 20 )hydrocarbyl group and a guanidine; and
one or more nucleic acid materials selected from the group consisting of DNA and RNA complexed to at least some of the nanoparticles,
wherein the nanoparticle-stabilized nanocapsule has a largest dimension of about 50 nm to about 1 μm.
2. The nanoparticle-stabilized nanocapsule of claim 1 , wherein the nanoparticle-stabilized nanocapsule comprises about 2 to about 100,000 of the nanoparticles.
3. The nanoparticle-stabilized nanocapsule of claim 2 , wherein the ligand is tethered to the quantum dot via a linker that comprises at least one of a (C 1 -C 20 )alkylene and a poly((C 2 -C 3 )alkoxy).
4. The nanoparticle-stabilized nanocapsule of claim 3 , wherein the nucleic acid material is selected from mRNA (messenger RNA), rRNA (ribosomal RNA), 7SL RNA or SRP RNA (signal recognition particle RNA), tRNA (transfer RNA), tmRNA (transfer-messenger RNA), snRNA (small nuclear RNA), snoRNA (small nucleolar RNA), SmY (SmY RNA), scaRNA (small Cajal body-specific RNA), gRNA (guide RNA), RNase P (ribonuclease P), RNase MRP (ribonuclease MRP), Y RNA, TERC (telomerase RNA component), SL RNA (spliced leader RNA), aRNA or asRNA (antisense RNA), cis-NAT (cis-natural antisense transcript), crRNA (CRISPR RNA), IncRNA (long noncoding RNA), miRNA (microRNA), piRNA (piwi-interacting RNA), siRNA (small interfering RNA), tasiRNA (trans-acting siRNA), rasiRNA (repeat associated siRNA), and 7SK (7SK RNA).
5. The nanoparticle-stabilized nanocapsule of claim 3 , wherein the nucleic acid material is siRNA (small interfering RNA).
6. The nanoparticle-stabilized nanocapsule of claim 3 , wherein the amphiphilic fluid is about 90 wt % to about 100 wt % of the nanodroplet.
7. The nanoparticle-stabilized nanocapsule of claim 6 , wherein the (C 5 -C 50 )hydrocarbyl is unsubstituted.
8. The nanoparticle-stabilized nanocapsule of claim 6 , wherein the amphiphilic compound has the structure:
wherein i is an integer from about 1 to about 1,000.
9. A nanoparticle-stabilized nanocapsule, consisting of:
a nanodroplet comprising an amphiphilic fluid, wherein the amphiphilic fluid is a compound having the structure of (C 5 -C 50 )hydrocarbyl-COOH, wherein the (C 5 -C 50 )hydrocarbyl is substituted or unsubstituted;
a plurality of nanoparticles deposed on a surface of the nanodroplet, each nanoparticle consisting of
a quantum dot comprising one or more of gold, iron oxide, cobalt ferrite, and silica, and
a ligand having the structure:
or a salt thereof, wherein each R is independently H or an alkyl group, m is an integer from about 0 to about 1,000, and n is an integer about 0 to about 1,000; and
one or more nucleic acid materials selected from the group consisting of DNA and RNA complexed to at least some of the nanoparticles, wherein the nanoparticle-stabilized nanocapsule has a largest dimension of about 50 nm to about 1 μm.
10. The nanoparticle-stabilized nanocapsule of claim 9 , wherein the nanoparticle-stabilized nanocapsule comprises about 2 to about 100,000 of the nanoparticles.
11. The nanoparticle-stabilized nanocapsule of claim 9 , wherein the nucleic acid material is selected from mRNA (messenger RNA), rRNA (ribosomal RNA), 7SL RNA or SRP RNA (signal recognition particle RNA), tRNA (transfer RNA), tmRNA (transfer-messenger RNA), snRNA (small nuclear RNA), snoRNA (small nucleolar RNA), SmY (SmY RNA), scaRNA (small Cajal body-specific RNA), gRNA (guide RNA), RNase P (ribonuclease P), RNase MRP (ribonuclease MRP), Y RNA, TERC (telomerase RNA component), SL RNA (spliced leader RNA), aRNA or asRNA (antisense RNA), cis-NAT (cis-natural antisense transcript), crRNA (CRISPR RNA), IncRNA (long noncoding RNA), miRNA (microRNA), piRNA (piwi-interacting RNA), siRNA (small interfering RNA), tasiRNA (trans-acting siRNA), rasiRNA (repeat associated siRNA), and 7SK (7SK RNA).
12. The nanoparticle-stabilized nanocapsule of claim 11 , wherein the nucleic acid material is siRNA (small interfering RNA).
13. The nanoparticle-stabilized nanocapsule of claim 9 , wherein the amphiphilic fluid is about 90 wt % to about 100 wt % of the nanodroplet.
14. The nanoparticle-stabilized nanocapsule of claim 13 , wherein the amphiphilic compound has the structure:
wherein i is an integer from about 1 to about 1,000.
15. The nanoparticle-stabilized nanocapsule of claim 9 , wherein each R is an alkyl group.
16. The nanoparticle-stabilized nanocapsule of claim 5 , wherein the amphiphilic fluid is about 100 wt % of the nanodroplet.
17. The nanoparticle-stabilized nanocapsule of claim 12 , wherein the amphiphilic fluid is about 100 wt % of the nanodroplet.